Kanjinti

Kanjinti (trastuzumab-anns) is used to treat stomach and breast cancer. Kanjinti is a biosimilar for herceptin (trastuzumab). Biosimilars are biologic drugs that are similar to the original medication with no meaningful differences in effectiveness or safety. Kanjinti may be covered by your Medicare or insurance plan.

With the Patient Assistance Program from Amgen, you can receive your medication free of charge for up to one year.